Q1 2021 revenue growth of 30.8% year-over-year, organic revenue growth of 23.8% Q1 2021 GAAP EPS of $0.37; non-GAAP EPS of $0.44, compared to $0.14 in Q1 2020 Raising fiscal year 2021 outlook on strong demand for the Company’s high-performance life science tools, scientific instruments and diagnostic solutions BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR)... Read more
Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings Guidance WALTHAM, Mass.–(BUSINESS WIRE)–May 4, 2021– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for... Read more
Revenue growth 12% on a reported basis, 8% organically Double-digit orders growth across all business segments, reflecting strong commercial momentum and underlying demand in critical infrastructure Adjusted EBITDA margin of 17.1%, up 480 basis points; net income as a percentage of revenue was 6.9%, up 350 basis points Reported net income of $87 million or... Read more
MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021. Record first quarter revenue reflects a strong start to 2021 Revenue for the first quarter of 2021 was $29.0 million, representing an 86% increase compared with $15.6 million... Read more
WALTHAM, Mass., April 29, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021. First Quarter 2021 Highlights First quarter revenue increased 59% to $9.91 billion. First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.88.... Read more
Record revenue of $694 million, up 30% year-over-year Record Non-GAAP net earnings of $143 million, up 68% year-over-year, and GAAP net income of $122 million, up 77% year-over-year Operating cash flow of $127 million, up 69% year-over-year, and free cash flow of $100 million, up 55% year-over-year Read more
About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly) Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a... Read more
MENLO PARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of... Read more
MENLO PARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of... Read more
WASHINGTON, April 22, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the first quarter 2021. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended April 2, 2021, net earnings were $1.7 billion, or $2.29 per diluted common share which represents a 182.5% year-over-year... Read more